AIRE and neoplasm: Importantly, the observed synergy in tumor rejection extended to PD1 immunotherapy also, as evidenced by the enhanced tumor rejection in Aire−/− mice treated with anti-PD1 and increased cytolytic activity of CD8+ TILs (Fig. 3b, c).